“This Biotech Stock [Incyte (INCY)] Eyes Fresh Entry With 522% Earnings Growth Seen”
January 18, 2026
“Medicine remains one of the most potentially rewarding of all investment areas. And Incyte (INCY) is a biotech stock flirting with a buy point as Wall Street predicts skyrocketing earnings ahead…
The firm is expected to post full-year earnings growth of 522% for 2025, before slowing to 15% growth for 2026, MarketSurge data shows...”
Looks like that ship has sailed.